Chromophobe hepatocellular carcinoma with abrupt anaplasia: A proposal for a new subtype of hepatocellular carcinoma with unique morphological and molecular features

Modern Pathology

Volumn 26, Issue 12, 2013, Pages 1586-1593

  Wood, Laura D ^a   Heaphy, Christopher M ^a   Daniel, Hubert Darius J ^a   Naini, Bita V ^b   Lassman, Charles R ^b   Arroyo, May R ^c   Kamel, Ihab R ^a   Cosgrove, David P ^a   Boitnott, John K ^a   Meeker, Alan K ^a   Torbenson, Michael S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UCLA MEDICAL CENTER   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

ALT; Hepatocellular carcinoma; Telomere

Indexed keywords

DAXX PROTEIN;

ADULT; ANAPLASTIC CARCINOMA; ARTICLE; ATRX GENE; CANCER CELL; CANCER SURGERY; CHROMOPHOBE HEPATOCELLULAR CARCINOMA; CHRONIC HEPATITIS; CLINICAL ARTICLE; CYTOPLASM; DAXX GENE; FEMALE; GENE; H3F3A GENE; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MICROSCOPY; MOLECULAR DIAGNOSIS; MOLECULAR MECHANICS; PATHOLOGIST; PHENOTYPE; PRIORITY JOURNAL; PSEUDOCYST; SEQUENCE ANALYSIS; SOMATIC MUTATION; TELOMERE; TELOMERE HOMEOSTASIS;

ANAPLASIA; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; TELOMERE;

EID: 84889095314     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.68     Document Type: Article

References (15)

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-1255.
2. Venook AP, Papandreou C, Furuse J, et al. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010;15(Suppl 4):5-13.
3. Torbenson M. Review of the clinicopathologic features of fibrolamellar carcinoma. Adv Anat Pathol 2007;14: 217-223. (Pubitemid 46659192)
4. Heaphy CM, Subhawong AP, Hong SM, et al. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol 2011;179:1608-1615.
5. Cesare AJ, Reddel RR. Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet 2010;11:319-330.
6. Henson JD, Reddel RR. Assaying and investigating alternative lengthening of telomeres activity in human cells and cancers. FEBS Lett 2010;584:3800-3811.
7. Heaphy CM, de Wilde RF, Jiao Y, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011;333:425.
8. Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012;482: 226-231.
9. Chen YJ, Hakin-Smith V, Teo M, et al. Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. Cancer Res 2006;66:6473-6476. (Pubitemid 44085598)
10. Xue Y, Gibbons R, Yan Z, et al. The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies. Proc Natl Acad Sci USA 2003;100:10635-10640. (Pubitemid 37140081)
11. Lewis PW, Elsaesser SJ, Noh KM, et al. Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. Proc Natl Acad Sci USA 2010;107: 14075-14080.
12. Sung WK, Zheng H, Li S, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet 2012;44:765-769.
13. Schirmacher P, Bedossa P, Roskams T, et al. Fighting the bushfire in HCC trials. J Hepatol 2011;55:276-277.
14. Kudo M. Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice. Int J Clin Oncol 2010;15:242-255.
15. Ross HM, Daniel HD, Vivekanandan P, et al. Fibrolamellar carcinomas are positive for CD68. Mod Pathol 2011;24:390-395.